Endocrine Abstracts

Background: Pegvisomant has demonstrated efficacy in attaining IGF1 normalisation in previously uncontrolled acromegalic patients. Improper or less than prescibed use may lead to suboptimal control.Aim: Evaluation of home educational program.Methods: Multicenter Flemish study in seven non-controlled acromegalic outpatients. All patients were trained for daily s.c. pegvisomant injection at home by one single specialist nurse during ...